Cytokine Release Syndrome - Epidemiology

Relevant Publications

Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system.

Issue Release: 2024

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC.

Issue Release: 2024

A multi-center real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in Large B-Cell Lymphomas.

Issue Release: 2024

Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research.

Issue Release: 2024

Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysis.

Issue Release: 2024

Foxp3 Treg control allergic skin inflammation by restricting IFN-γ-driven neutrophilic infiltration and NETosis.

Issue Release: 2024

Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines.

Issue Release: 2024

Heat shock protein 90α reduces CD8 T cell exhaustion in acute lung injury induced by lipopolysaccharide.

Issue Release: 2024

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Issue Release: 2024

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.

Issue Release: 2024

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.

Issue Release: 2024

Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma.

Issue Release: 2024

IL-6 knockdown in a model of the human bone marrow, abrogates DNA damage induction in bystander cells post-chemotherapy induced cytokine release syndrome.

Issue Release: 2024

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.

Issue Release: 2024

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.

Issue Release: 2024

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology.

Issue Release: 2024

SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma.

Issue Release: 2024

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma.

Issue Release: 2024

Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors.

Issue Release: 2024

What is Inflammatory Bowel Disease (IBD)?

Why is Clinical Effectiveness Important?

What Constitutes Nutritious Foods?

How is Hadoop Applied in Epidemiological Studies?

What is a Jacobian Matrix?

Why is JHA Important in Epidemiology?

What is Vaccine Effectiveness?

What are the Preventive Measures for Cardiovascular Disease?

How Does Epidemiology Play a Role?

What are Measures in Epidemiology?

Cytokine Release Syndrome - Epidemiology

Relevant Publications

Partnered Content Networks

Relevant Topics